Document Detail

Filgrastim: new indication. AIDS-associated neutropenia: another soft indication.
MedLine Citation:
PMID:  11718177     Owner:  HSR     Status:  MEDLINE    
(1) Neutropenia is frequent in patients with AIDS and is an added risk factor for infection. There is no specific treatment, except, when feasible, the withdrawal of a suspected culprit drug. (2) Filgrastim, a granulocyte growth factor, has been granted a license extension to cover the treatment of persistent neutropenia in patients at an advanced stage of HIV infection. (3) Only one comparative, unblinded trial has been published in this setting. It involved 258 patients distributed into three groups, who received daily filgrastim, intermittent filgrastim, or no treatment. Six months after the beginning of the trial, filgrastim had not reduced the number of deaths, the number of hospital days, or the risk of bacterial or fungal infection. (4) The trial report fails to show whether filgrastim influences viral load or the CD4+ lymphocyte count. (5) In the absence of published dose-finding studies there is no proof that the dose regimen recommended in the licensing terms is the one with the best risk-benefit ratio. (6) Treatment with filgrastim is costly, especially as the available unit doses are unsuitable for this indication. (7) Patients at an advanced stage of HIV infection are already heavily medicated. There is no reason to add filgrastim, which has no proven clinical value.
Related Documents :
20857187 - Neurocognitive impairment and medication adherence in hiv patients with and without coc...
17537997 - Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in...
20425057 - Antiretroviral adherence interventions: translating research findings to the real world...
12537147 - Non-adherence to hiv antiretroviral medications: 'the drugs are working and i'm a conti...
20588167 - Increased epicardial adipose tissue volume in hiv-infected men and relationships to bod...
20957327 - Hiv-infection as a self-reported risk factor for attempted suicide in south africa.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  10     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2001 Aug 
Date Detail:
Created Date:  2001-11-21     Completed Date:  2002-02-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  France    
Other Details:
Languages:  eng     Pagination:  106-7     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acquired Immunodeficiency Syndrome / complications
Clinical Trials as Topic
Cost-Benefit Analysis
Filgrastim / administration & dosage,  adverse effects,  economics,  therapeutic use*
Granulocyte Colony-Stimulating Factor / administration & dosage,  adverse effects,  economics,  therapeutic use
Neutropenia / drug therapy*,  etiology
Treatment Outcome
Reg. No./Substance:
121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acupuncture: searching for benefits.
Next Document:  Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure...